BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.   

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.

Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.

Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.

Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.

Leadership succession is proceeding within South Korean pharmaceutical corporations such as Daiichi Sankyo Korea, Astellas Pharma Korea, Kyowa Kirin Korea as well as MSD Korea.

The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.

Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.

Industry is researching alternatives to PVC for medicines packaging, but content integrity must remain paramount, says Circpack consultancy’s Filipe Viera de Castro, who puts the case for companies to contribute to waste management costs.

An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.

During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.

Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024.

An interactive look at pharma, medtech and diagnostics deals made during April 2024. Data courtesy of Biomedtracker.

Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.

The FTC is intensifying its crackdown on pharmaceutical companies' misuse of patent listings as industry seeks clearer guidelines.

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve access to lifesaving therapies. Payers and politicians must be persuaded to loosen their purse strings – and open their minds.

Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

During Q1, biopharma merger and acquisition deal value reached $37bn, while the potential deal value from alliances was $38.5bn. Device company M&A values reached $3.6bn, while in vitro diagnostics and research tools players’ M&A activity totaled $1bn.

Wales must be better at adoption, said Mike Emery, the Welsh government’s digital and innovation officer for health and social care, in conversation with In Vivo.

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Industry is researching alternatives to PVC for medicines packaging, but content integrity must remain paramount, says Circpack consultancy’s Filipe Viera de Castro, who puts the case for companies to contribute to waste management costs.